2024-07-08 21:00:00 ET
Summary
- iTeos Therapeutics is developing an anti-TIGIT molecule for various cancers, partnering with GSK and advancing to late-stage clinical studies.
- Their main clinical focus is belrestotug, aiming to differentiate from other anti-TIGIT approaches, with positive interim data readouts.
- Financially, ITOS has a strong balance sheet with significant cash reserves, but faces risks from unproven TIGIT targets and market valuation fluctuations.
Topline Summary and Update
Read the full article on Seeking Alpha
For further details see:
iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism